Nikko Asset Management Americas Inc. 13D and 13G filings for CRISPR Therapeutics AG:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-02-12 6:22 pm Sale | 2023-12-31 | 13G | CRISPR Therapeutics AG CRSP | Nikko Asset Management Americas Inc. | 3,369,762 4.240% | -636,714![]() (-15.89%) | Filing |
2023-02-10 10:30 am Sale | 2022-12-31 | 13G | CRISPR Therapeutics AG CRSP | Nikko Asset Management Americas Inc. | 4,006,476 5.110% | -312,995![]() (-7.25%) | Filing |
2022-02-14 06:05 am Purchase | 2021-12-31 | 13G | CRISPR Therapeutics AG CRSP | Nikko Asset Management Americas Inc. | 4,319,471 5.640% | 482,648![]() (+12.58%) | Filing |
2021-02-11 5:14 pm Purchase | 2020-12-31 | 13G | CRISPR Therapeutics AG CRSP | Nikko Asset Management Americas Inc. | 3,836,823 5.390% | 787,270![]() (+25.82%) | Filing |
2020-02-12 3:19 pm Purchase | 2019-12-31 | 13G | CRISPR Therapeutics AG CRSP | Nikko Asset Management Americas Inc. | 3,049,553 5.080% | 3,049,553![]() (New Position) | Filing |